Table 3.
Associations of HbA1c With ESRD: Competing-Risk Model With Death as Competing Risk
| HbA1c < 6% | HbA1c 7%–7.9% | HbA1c 8%–8.9% | HbA1c ≥ 9% | |
|---|---|---|---|---|
| Unadjusted | 1.10 (0.68–1.78) | 1.18 (0.80–1.73) | 1.31 (0.82–2.11) | 3.15 (2.17–4.57) |
| Adjusted for | ||||
| 1) Age, race, sex | 0.98 (0.61–1.59) | 1.05 (0.73–1.55) | 1.07 (0.66–1.73) | 1.95 (1.32–2.87) |
| 2) 1 + comorbid conditions, BMI group, albumin, hemoglobin, smoking | 0.87 (0.53–1.41) | 0.99 (0.67–1.47) | 1.02 (0.62–1.68) | 1.76 (1.15–2.67) |
| 3) 2 + ACEi/ARB, statin, β-blocker, eGFR, proteinuria | 0.58 (0.32–1.02) | 0.92 (0.62–1.37) | 0.65 (0.38–1.12) | 1.35 (0.88–2.09) |
Note: Values given as subdistribution hazard ratio (95% confidence interval). Estimates combined using MIanalyze on the 5 imputed data sets. Reference category is 6% to 6.9%.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HbA1c, hemoglobin A1c.